AcelRx Still Gets Little Valuation For Dsuvia
AcelRx is ready to launch Dsuvia, its proprietary sublingual formulation of sufentanil. Dsuvia was developed to be a safer, faster-acting opioid alternative to intravenous morphine for acute pain in hospital settings. It relives pain faster than morphine, has a well-defined period of efficacy, and an abuse resistant formulation. Dsuvia was designed to be administered without the necessary equipment and set up time for intravenous morphine, reducing time to relief for the patient and shortening treatment times in the Emergency Room. The reduction in equipment and increased turnover of